Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). CA-4948 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The chemotherapy drugs used in FOLFOX, fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin is used with fluorouracil to treat colorectal cancer. Bevacizumab is in a class of medications called anti-angiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of the tumor. Giving CA-4948 with FOLFOX plus bevacizumab may be safe, tolerable and/or effective in treating patients with metastatic colorectal cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie lub cytologicznie rak gruczolakowaty jelita grubego
- •Wiek co najmniej 18 lat
- •Zmiany nowotworowe widoczne na obrazach (tomografia, rezonans)
- •Ogólny stan zdrowia umożliwiający leczenie (nie więcej niż umiarkowana słabość)
- •Wystarczająco dobre funkcje wątroby, nerek i szpiku kostnego (badania krwi)
- •Pacjenci z HIV mogą uczestniczyć, jeśli przyjmują leki antyretrowirusowe i wirus jest w krwi niewykrywalny
- •Pacjenci z wirusem zapalenia wątroby typu B lub C mogą uczestniczyć, jeśli choroba jest kontrolowana
✗ Disqualifies
- •Wiek poniżej 18 lat
- •Znacznie osłabione funkcje wątroby, nerek lub szpiku kostnego
- •Podwyższony poziom enzymów mięśniowych (CPK) lub zbyt wysoki cholesterol nierekontrolowany lekami
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
UF Health Cancer Institute - Gainesville
Gainesville, United States
Memorial Hospital East
Shiloh, United States
University of Kansas Clinical Research Center
Fairway, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Hospital-Indian Creek Campus
Overland Park, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood, United States
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, United States
Siteman Cancer Center at West County Hospital
Creve Coeur, United States
Washington University School of Medicine
St Louis, United States
Siteman Cancer Center-South County
St Louis, United States
Siteman Cancer Center at Christian Hospital
St Louis, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Vanderbilt University/Ingram Cancer Center
Nashville, United States
Trial contact
Site Public Contact
Thomas J. George
PRINCIPAL_INVESTIGATOR
Site Public Contact
Moh'd Khushman
PRINCIPAL_INVESTIGATOR
Site Public Contact
Raed Al-Rajabi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Susanna V. Ulahannan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kristen K. Ciombor
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.